| abstract |
The present invention reveals recombinant human antibodies that recognize human Vascular Endothelial Growth Factor-A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effects in vitro and pro-angiogenic in vivo. These antibodies identify an epitope in human VEGF-A unlike any other previously reported and were obtained by combining the same immunoglobulin light chain variable region with three other heavy chain ones. Antibodies were obtained by mutagenesis of variable regions of human immunoglobulins, and can be used for immunotherapy of pathological entities whose course is associated with increased vasculature, such as age-related macular degeneration, cancer, and others. |